Fei Jie
Overview
Explore the profile of Fei Jie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bartlett N, Hahn U, Kim W, Fleury I, Laribi K, Bergua J, et al.
J Clin Oncol
. 2025 Jan;
43(9):1061-1072.
PMID: 39772655
Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy...
2.
Manitz J, Kan-Dobrosky N, Buchner H, Casadebaig M, Degtyarev E, Dey J, et al.
Pharm Stat
. 2021 Oct;
21(1):150-162.
PMID: 34605168
An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives...
3.
Kollmannsberger C, Choueiri T, Heng D, George S, Jie F, Croitoru R, et al.
Oncologist
. 2020 Dec;
26(3):182-e361.
PMID: 33289953
Lessons Learned: The primary endpoint of this phase II study that evaluated the efficacy and safety of the investigational compound, AGS-16C3F, versus axitinib in previously treated patients with metastatic renal...
4.
Bhaumik D, Jie F, Nordgren R, Bhaumik R, Sinha B
IEEE Trans Med Imaging
. 2018 Jul;
37(11):2381-2389.
PMID: 29994089
The human brain is an amazingly complex network. Aberrant activities in this network can lead to various neurological disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, and autism. functional...
5.
Yu H, Spira A, Horn L, Weiss J, West H, Giaccone G, et al.
Clin Cancer Res
. 2017 Sep;
23(24):7467-7473.
PMID: 28954786
Acquired T790M mutations are the most frequently identified resistance mechanism to EGFR tyrosine kinase inhibitors (TKI) in patients with -mutant lung cancers. ASP8273 is a third-generation EGFR TKI with antitumor...
6.
Mateo J, Olmos D, Dumez H, Poondru S, Samberg N, Barr S, et al.
Br J Cancer
. 2016 Mar;
114(8):889-96.
PMID: 27002938
Background: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition....
7.
Papadopoulos K, Lopez-Jimenez J, Smith S, Steinberg J, Keating A, Sasse C, et al.
Leuk Lymphoma
. 2016 Feb;
57(8):1848-55.
PMID: 26857688
This phase II study evaluated YM155, a novel small-molecule survivin suppressant, in combination with rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma (NHL) who failed or were not candidates...
8.
Clemens M, Gladkov O, Gartner E, Vladimirov V, Crown J, Steinberg J, et al.
Breast Cancer Res Treat
. 2014 Dec;
149(1):171-9.
PMID: 25547219
The objective of this study was to assess the efficacy and tolerability of YM155, a survivin suppressor, in combination with docetaxel, compared with docetaxel alone in patients with HER2-negative metastatic...
9.
Kudchadkar R, Ernst S, Chmielowski B, Redman B, Steinberg J, Keating A, et al.
Cancer Med
. 2014 Dec;
4(5):643-50.
PMID: 25533314
Survivin is a microtubule-associated protein believed to be involved in preserving cell viability and regulating tumor cell mitosis, and it is overexpressed in many primary tumor types, including melanoma. YM155...
10.
Boggiatto P, Jie F, Ghosh M, Gibson-Corley K, Ramer-Tait A, Jones D, et al.
Am J Pathol
. 2009 Apr;
174(5):1818-26.
PMID: 19349356
Initiation of productive immune responses against Leishmania depends on the successful transition of dendritic cells (DC) from an immature to a mature phenotype. This process is characterized by high CD40...